Check for updates

OPEN ACCESS

EDITED BY Xianping Du, Rutgers, The State University of New Jersey -Busch Campus, United States

REVIEWED BY Xudong Chen, Huaihua First People's Hospital, China Youming Tang, Zhejiang University of Science and Technology, China

*CORRESPONDENCE Xiangning Yuan 🖾 xiangning.yuan@foxmail.com

[†]These authors have contributed equally to this work and share first authorship

RECEIVED 31 August 2023 ACCEPTED 30 October 2023 PUBLISHED 30 November 2023

CITATION

Mo H, Fan F, Liu J, Zhang W, Wang Q and Yuan X (2023) Chronic kidney disease as a predictive factor for poor prognosis in traumatic brain injury among older adults: a case-control study. *Front. Neurol.* 14:1286592. doi: 10.3389/fneur.2023.1286592

COPYRIGHT

© 2023 Mo, Fan, Liu, Zhang, Wang and Yuan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Chronic kidney disease as a predictive factor for poor prognosis in traumatic brain injury among older adults: a case-control study

Haoyang Mo^{1,2†}, Fan Fan^{1,2†}, Jian Liu^{1,2}, Wenfan Zhang³, Qing Wang⁴ and Xiangning Yuan⁵*

¹Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China, ²National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China, ³Department of Medical Record, Xiangya Hospital, Central South University, Changsha, Hunan, China, ⁴Department of Interventional Medicine and Vascular Surgery, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan, China, ⁵Department of Nephrology, Xiangya Hospital, Central South University, Changsha, Hunan, China

Objective: Traumatic brain injury (TBI) is a highly prevalent neurological disorder that affects a gradually increasing proportion of older adults. Chronic kidney disease (CKD) significantly contributes to global years of life lost, with an estimated one-tenth of the global population affected by CKD. However, it remains unclear whether CKD impacts TBI prognosis. We conducted a case-control study to investigate the clinical outcomes of TBI patients with or without CKD comorbidity and identified the risk factors associated with a poor prognosis.

Methods: From January 2017 through April 2023, 11 patients with TBI and CKD were included, and 27 control TBI cases with normal kidney function were matched by age, gender, and admission Glasgow Coma Scale (GCS) score as the control group.

Results: The CKD TBI group had a significantly lower GCS score upon discharge (7.1 \pm 5.9) compared to the non-CKD TBI group (13.1 \pm 2.6) (p < 0.01). ICU stay time and hospitalization expenses were higher in the CKD group than the non-CKD group, though there were no statistical differences. Additionally, patients in the CKD TBI group had a higher frequency of hospital-acquired infections (54.4%) compared with those in the non-CKD TBI group (7.4%) (p < 0.01). The two groups exhibited no differences in hemoglobin levels, albumin levels, or coagulation function. Logistic regression analysis showed that advanced age, low admission GCS score, elevated blood urea, and creatinine levels were associated with a poor neurological prognosis.

Conclusion: TBI patients comorbid with CKD have a poorer prognosis than those with normal kidney function.

KEYWORDS

traumatic brain injury, clinical research, prognosis, chronic kidney disease, glasgow coma scale score, serum creatine

1 Introduction

Traumatic brain injury (TBI) is a highly prevalent neurological disorder that is impacting a gradually increasing proportion of elderly patients. Falls and road traffic accidents are the leading causes of TBI. The acute injury caused by TBI and the ensuing long-term functional impairments that present themselves during rehabilitation significantly burden patients' health (1–3). Chronic kidney disease (CKD) is a significant contributor to global years of life lost, and an estimated one-tenth of the global population may be affected by CKD. The rising prevalence of chronic conditions such as diabetes, hypertension, and obesity elevates the magnitude of CKD as a pressing public health concern (4–6).

A growing amount of attention is being given to brainkidney interactions, and some studies have explored the association between TBI and kidney dysfunction, with the majority of the research focusing on the relationship between TBI and post-traumatic acute kidney injury (AKI) (7, 8). Although the mechanisms are not fully understood, potential factors contributing to TBI-induced AKI include post-injury inflammation and the dysregulation of catecholamine release (9). Wu et al. reported that an increased risk of long-term CKD development was associated with TBI (10). However, it remains unclear whether CKD impacts TBI prognosis. Therefore, we conducted a casecontrol study to investigate the clinical outcomes of older TBI patients comorbid with CKD and identified the risk factors associated with a poor prognosis.

2 Methods

This retrospective case-control study did not involve traceable personal information, and patient consent was not required. The ethics committee of Xiangya Hospital, Central South University, approved the study. This study was reported following guidelines written according to the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) statement (11).

2.1 Participants

From January 2017 through April 2023, brain injury patients admitted to Xiangya Hospital of Central South University were included in the trial if they had traumatic brain injury, were aged \geq 65 years old, and had CKD [eGFR < 60 mL/(min·1.73 m²) lasting for at least 3 months].

2.2 Data collection

The medical records and relevant examination data of the included patients were retrieved from our medical center's electronic medical record system. The demographic data included the patients' age, gender, admission Glasgow Coma Scale (GCS) score, mechanism of injury, lesions of injuries, and history of pre-existing chronic diseases. After reviewing each patient's computed tomography (CT) scan data, we documented radiological features such as epidural hematoma, subdural

hematoma, cerebral contusion, and other relevant findings. The biochemical parameters of the patients mainly included the initial admission levels of hemoglobin (Hb), albumin (Alb), serum urea, serum creatinine (Cr), coagulation function parameters, and etiological culture results.

2.3 Outcomes

The primary outcomes included the patients' discharge GCS score, infection status during hospitalization, number of days of hospital stay, number of days of intensive care unit (ICU) stay, and hospitalization expenses. The secondary outcome measure was the difference in discharge and admission GCS scores. If the discharge GCS score was lower than the admission GCS score, the patient was defined as having an unfavorable outcome.

2.4 Statistical analysis

Categorical data are presented as counts and percentages, and continuous data are expressed as mean \pm standard deviation or median (interquartile range). A comparison between categorical data was performed using the chi-square test, and continuous data were compared using the *t*-test or non-parametric tests.


To investigate the relative risk of potential predictor variables, univariate logistic regression was applied to obtain the odds ratios (ORs) and 95% confidence intervals (CIs). Based on the significant factors identified in the univariate analysis, a receiver operating characteristic (ROC) curve model was established. The model's discriminatory power was evaluated by calculating the area under the curve (AUC) of the ROC curve. The cutoff value was determined by maximizing the Youden index in the ROC curve analysis. A *p*-value of < 0.05 was considered statistically significant. All data analysis was performed using R version 4.1.0.

3 Results

3.1 Patient inclusion and characteristics

From January 2017 through April 2023, 1,736 brain injury patients were admitted to Xiangya Hospital of Central South University. Of these, 289 cases of chronic subdural hematoma, 1,120 cases under the age of 65, and 10 cases of AKI were excluded. Finally, 11 cases of TBI comorbid with CKD were screened (CKD TBI group). A total of 27 TBI patients with normal kidney function were matched for age, gender, and admission GCS scores and included in the control group (non-CKD TBI group) (Figure 1).

A total of 38 TBI patients were analyzed. Table 1 presents their baseline characteristics. The average age of the 38 patients was 70.5 ± 4.5 years, and there were 31 males (81.6%) (Table 1). The GCS score on admission was 11.6 \pm 2.7. Falling was the most common mechanism of injury, accounting for 47.4% of all injuries. Other mechanisms included traffic accidents (36.8%) and assaults (5.3%). Imaging examinations revealed intracranial lesions, including epidural hematoma (13.2%),



subdural hematoma (55.3%), and cerebral contusion (65.8%) (Table 1).

Patients in the CKD TBI group had a higher frequency of comorbidities such as hypertension, diabetes, and coronary heart disease (p < 0.05) (Table 1). We also recorded detailed laboratory markers upon the patients' admission. The average values for Hb and Alb were 108.8 g/L and 32.9 g/L, respectively. The patients in the CKD TBI group had lower levels of Hb and Alb compared to the non-CKD TBI group, although the differences were not statistically significant. There was no difference in coagulation function between the two groups. Regarding renal function markers, patients from the CKD TBI group showed significantly higher levels of serum urea (18.2 ± 10.9 mmol/L) and serum creatinine (307.1 ± 197.5 μ mol/L) than patients from the non-CKD TBI group, with values of 5.0 ± 1.4 mmol/L and 75.9 ± 13.6 μ mol/L, respectively (p < 0.01) (Table 1).

3.2 Clinical outcomes

Next, we compared the overall outcomes of the two patient groups upon discharge (Table 2). It is worth noting that the patients from the CKD TBI group had a significantly lower GCS scores upon discharge (7.1 \pm 5.9) compared with the non-CKD TBI group (13.1 \pm 2.6) (p < 0.01). The median length of hospital stay was comparable between the two groups. Patients in the CKD TBI group spent longer in the ICU, and their overall hospitalization costs were higher than those of the non-CKD TBI group. However, the differences were not statistically significant.

Additionally, patients in the CKD TBI group had a higher frequency of hospital-acquired infections (54.4%) compared with the non-CKD TBI group (7.4%) (p < 0.01) (Table 2). Four patients in the CKD TBI group experienced multi-species and multi-site infections with various pathogens, including gram-negative

TABLE 1 Baseline characteristics of included patients.

	ALL	Non- CKD	CKD	<i>P</i> value	
	N = 38	N = 27	N = 11		
Age (y)	70.5 (4.5)	69.7 (4.3)	72.5 (4.7)	0.107	
Sex, n (%)	0.648				
Female	7 (18.4)	6 (22.2)	1 (9.1)		
Male	31 (81.6)	21 (77.8)	10 (90.9)		
GCS admission	11.6 (2.7)	12.1 (2.5)	10.5 (3.0)	0.126	
Mechanism, n (%)				0.938	
Traffic accident	14 (36.8)	10 (37.0)	4 (36.4)		
Falling	18 (47.4)	13 (48.1)	5 (45.5)		
Assault	2 (5.3)	1 (3.7)	1 (9.1)		
Other	4 (10.5)	3 (11.1)	1 (9.1)		
Location of lesions, n (%)					
EDH	5 (13.2)	4 (14.8)	1 (9.1)	1.000	
SDH	21 (55.3)	13 (48.1)	8 (72.7)	0.282	
Cerebral contusion	25 (65.8)	17 (63.0)	8 (72.7)	0.714	
Medical history, n (%)					
Hypertension	21 (55.3)	11 (40.7)	10 (90.9)	0.010	
Diabetes	6 (15.8)	1 (3.7)	5 (45.5)	0.005	
CHD	10 (26.3)	3 (11.1)	7 (63.6)	0.002	
Stroke	2 (5.3)	2 (7.4)	0 (0.0)	1.000	
Hb (g/L)	108.8 (22.2)	110.2 (22.9)	105.2 (20.7)	0.517	
Alb (g/L)	32.9 (5.7)	33.2 (6.0)	32.3 (5.1)	0.645	
Urea (mmol/L)	8.8 (8.4)	5.0 (1.4)	18.2 (10.9)	0.002	
Cr (µmol/L)	142.8 (148.2)	75.9 (13.6)	307.1 (197.5)	0.003	
PT, n (%)	0.295				
Long	5 (13.5)	5 (19.2)	0 (0.0)		
Normal	32 (86.5)	21 (80.8)	11 (100.0)		
APTT, n (%)	0.540				
Long	3 (8.1)	3 (11.5)	0 (0.0)		
Normal	34 (91.9)	23 (88.5)	11 (100.0)		

CKD, chronic kidney disease; GCS, glasgow coma scale; EDH, epidural hematoma; SDH, subdural hematoma; CHD, coronary heart disease; Hb, hemoglobin; Alb, albumin; Cr, creatinine; PT, prothrombin time; APTT, activated partial thromboplastin time.

bacteria, gram-negative cocci, and fungi. The most common site of infection was the lungs, followed by the urinary tract and central nervous system.

Furthermore, we conducted linear regression analysis on both groups' admission and discharge GCS scores (Figure 2). The CKD TBI group showed a fitted curve with an R-value of 0.93 (p < 0.001), while the non-CKD TBI group had a fitted curve with an R-value of 0.49 (p < 0.01). Among the TBI patients with lower admission GCS scores, those with comorbid CKD had lower GCS scores upon discharge than those without CKD. Conversely, for patients in both

TABLE 2 Comparison of clinical outcomes between TBI patients with CKD and without CKD.

	ALL N = 38	Non-CKD <i>N = 27</i>	CKD N = 11	P value
Hospital stay (days)	14.0 (9.0, 19.8)	14.0 (9.5, 18.5)	13.0 (7.5, 29.0)	0.847
ICU stay (days)	3.0 (0.0, 12.8)	3.0 (0.0, 9.5)	10.0 (1.0, 29.0)	0.115
Cost (¥)	113,358.9 (43,541.0, 154,290.8)	110,152.7 (39,286.9, 132,064.2)	146,633.3 (48,707.2, 361,544.5)	0.111
GCS discharge	11.4 (4.7)	13.1 (2.6)	7.1 (5.9)	0.007
Infection,	0.004			
No	30 (78.9)	25 (92.6)	5 (45.5)	
Yes	8 (21.1)	2 (7.4)	6 (54.5)	

CKD, chronic kidney disease; ICU, intensive care unit; GCS, glasgow coma scale.

groups with higher admission GCS scores, higher GCS scores were observed upon discharge.

3.3 Association of renal indicators with outcomes

After defining a discharge GCS score lower than the admission GCS score as a indicator of an unfavorable outcome, we calculated the ORs for the relevant indicators in univariate logistic models for adverse prognostic outcomes (Table 3). Advanced age upon admission, low admission GCS score, and high levels of initial serum urea and serum creatinine were closely associated with poor TBI outcomes.

Next, we constructed ROC curves to explore the ability of serum urea and serum creatinine to predict adverse outcomes in TBI (Figure 3). The results indicated that serum urea and serum creatinine can be used to predict poor prognostic outcomes in TBI, with AUCs of 0.877 and 0.828, respectively. The optimal cutoff values for serum urea and creatinine were 10.97 (mmol/L) and 129.50 (μ mol/L), respectively.

4 Discussion

Aging is a global problem, and TBI has become increasingly prevalent among older adults (12). With the increase in the prevalence of chronic diseases such as diabetes in adults, the burden of renal failure is also increasing (13). This case-control study analyzed the clinical outcomes and risk factors of TBI patients with CKD comorbidity. Among cases with similar severity of brain injury, TBI patients with concurrent CKD generally exhibited poorer outcomes compared to the general TBI population.

TBI patients with concurrent CKD constitute a high-risk population in neurointensive care and require special attention from treating physicians. Our study identified urea and creatinine as serum biomarkers that can be used to predict adverse outcomes in TBI events. As renal function progressively declines, CKD




TABLE 3 Univariate logistic regression for independent variables related to poor outcomes.


	OR (95% CI)	P value
Age	1.30 (1.06, 1.60)	0.013
GCS admission	0.56 (0.37, 0.85)	0.006
Urea	1.47 (1.12, 1.93)	0.006
Cr	1.01 (1.00, 1.02)	0.017

OR, odds ratio; GCS, glasgow coma scale; Cr, creatinine.

patients may experience various complications such as anemia, malnutrition, and coagulation dysfunction (6). However, when we compared hemoglobin levels, serum albumin levels, and coagulation function indexes between the CKD TBI group and the non-CKD TBI group in this study, there were no statistical differences between the two groups, and logistic regression did not indicate that these indexes affect the prognosis of TBI patients.

This study found that patients with TBI comorbid with CKD had a higher prevalence of chronic diseases, such as hypertension, diabetes, and coronary heart disease. These diseases can cause arteriosclerosis or worse vascular conditions, which may be related to a worse prognosis for TBI patients with CKD (14, 15). In addition, CKD patients tend to have internal environment disorders such as azotemia. The accumulation of various metabolic substances in CKD may exacerbate the severity of brain injury in TBI patients (16, 17). For instance, guanidine compounds, a group of uremic neurotoxins, have neurotoxic and vascular toxic effects on neurons and blood vessels (18). Another uremic neurotoxin, asymmetric dimethylarginine, may affect cerebral blood flow and decrease cerebral perfusion (19). Azotemia in CKD patients can also exacerbate brain injury, which manifests as an aggravation of post-traumatic brain edema by disrupting the blood-brain barrier via osmotic pressure disturbances.

CKD patients are prone to infection. As CKD is a systemic disease, prolonged energy insufficiency, the accumulation of



various inflammatory mediators, and the dysregulation of the autonomic nervous system may attenuate immunity in patients (20, 21). In this study, we observed a significantly higher incidence of infection in TBI patients with comorbid CKD compared to the non-CKD group. Moreover, multiple pathogens and multiple site infections were more common in TBI patients comorbid with CKD and may lead to a prolonged ICU stay and increased hospitalization costs. Therefore, doctors need to monitor for infection in TBI patients comorbid with CKD and be alert to hospital-acquired infections.

There were several limitations in our study. Firstly, this study was inherently a single-center retrospective case-control study with a relatively small number of patients included, which may restrict the generalizability of our conclusions. Therefore, caution should be exercised when extending our findings to a broader population. Further validation of our findings is warranted through prospective studies based on larger cohorts. Secondly, due to limitations in the original medical records data, we used the discharge GCS score as the outcome measure, but data on the longterm prognosis of patients after discharge should be collected as further evaluation criteria. Thirdly, it is worth noting that other underlying comorbidities in the elderly population may act as confounding factors that influence the interpretation of our results. Future research should consider incorporating additional relevant factors in the case matching process.

In summary, TBI patients comorbid with CKD have a poorer prognosis than those with normal kidney function. Elevated serum urea and creatine levels are considered risk factors for poorer clinical prognosis in older TBI patients.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

Ethics statement

The studies involving humans were approved by the Ethics Committee of Xiangya Hospital, Central South University. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

Author contributions

HM: Data curation, Formal analysis, Funding acquisition, Visualization, Writing – original draft. FF: Data curation, Formal analysis, Project administration, Resources, Writing – review & editing. JL: Data curation, Formal analysis, Writing – review & editing. WZ: Data curation, Formal analysis, Writing – review & editing. QW: Writing – review & editing. XY: Conceptualization, Funding acquisition, Resources, Supervision, Writing – review & editing.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by National Natural Science Foundation of China

References

1. Stocchetti N, Zanier ER. Chronic impact of traumatic brain injury on outcome and quality of life: a narrative review. *Crit Care.* (2016) 20:148. doi: 10.1186/s13054-016-1318-1

2. Roozenbeek B, Maas AIR, Menon DK. Changing patterns in the epidemiology of traumatic brain injury. Nat Rev Neurol. (2013) 9:231-6. doi: 10.1038/nrneurol.2013.22

3. Capizzi A, Woo J, Verduzco-Gutierrez M. Traumatic brain injury: an overview of epidemiology, pathophysiology, and medical management. *Med Clin North Am.* (2020) 104:213–38. doi: 10.1016/j.mcna.2019.11.001

4. Coresh J. Update on the burden of CKD. JASN. (2017) 28:1020-2. doi: 10.1681/ASN.2016121374V

5. Glassock RJ, Warnock DG, Delanaye P. The global burden of chronic kidney disease: estimates, variability and pitfalls. *Nat Rev Nephrol.* (2017) 13:104–14. doi: 10.1038/nrneph.2016.163

6. Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management. JAMA. (2019) 322:1294. doi: 10.1001/jama.2019.14745

7. Udy AA, Jarrett P, Lassig-Smith M, Stuart J, Starr T, Dunlop R, et al. Augmented renal clearance in traumatic brain injury: a single-center observational study of atrial natriuretic peptide, cardiac output, and creatinine clearance. *J Neurotrauma*. (2017) 34:137–44. doi: 10.1089/neu.2015.4328

8. Barea-Mendoza JA, Chico-Fernández M, Quintana-Díaz M, Serviá-Goixart L, Fernández-Cuervo A, Bringas-Bollada M, et al. Traumatic brain injury and acute kidney injury-outcomes and associated risk factors. *JCM*. (2022) 11:7216. doi: 10.3390/jcm11237216

9. De Vlieger G, Meyfroidt G. Kidney dysfunction after traumatic brain injury: pathophysiology and general management. *Neurocrit Care.* (2023) 38:504–16. doi: 10.1007/s12028-022-01630-z

10. Wu C-L, Kor C-T, Chiu P-F, Tsai C-C, Lian I-B, Yang T-H, et al. Long-term renal outcomes in patients with traumatic brain injury: A nationwide population-based cohort study. *PLoS ONE.* (2017) 12:e0171999. doi: 10.1371/journal.pone.0171999

11. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. *Lancet.* (2007) 370:1453–7. doi: 10.1016/S0140-6736(07)61602-X

(81900679) and Health and Family Planning Commission of Hunan Province (B20180889).

Acknowledgments

The authors wish to thank all the doctors in the neurology and nephrology departments who participated in the diagnosis and treatment of these patients.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

12. Rauen K, Späni CB, Tartaglia MC, Ferretti MT, Reichelt L, Probst P, et al. Quality of life after traumatic brain injury: a cross-sectional analysis uncovers ageand sex-related differences over the adult life span. *GeroScience*. (2021) 43:263–78. doi: 10.1007/s11357-020-00273-2

13. Kelly DM, Anders H-J, Bello AK, Choukroun G, Coppo R, Dreyer G, et al. International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in Western Europe. *Kidney Int Suppl.* (2021) 11:e106–18. doi: 10.1016/j.kisu.2021. 01.007

14. Vervloet M, Cozzolino M. Vascular calcification in chronic kidney disease: different bricks in the wall? *Kidney Int.* (2017) 91:808–17. doi: 10.1016/j.kint.2016.09.024

15. Hobson S, Arefin S, Witasp A, Hernandez L, Kublickiene K, Shiels PG, et al. Accelerated vascular aging in chronic kidney disease: the potential for novel therapies. *Circ Res.* (2023) 132:950–69. doi: 10.1161/CIRCRESAHA.122.32 1751

16. Afsar B, Sag AA, Yalcin CE, Kaya E, Siriopol D, Goldsmith D, et al. Brainkidney cross-talk: definition and emerging evidence. *Eur J Intern Med.* (2016) 36:7–12. doi: 10.1016/j.ejim.2016.07.032

17. Tanaka S, Okusa MD. Crosstalk between the nervous system and the kidney. *Kidney Int.* (2020) 97:466–76. doi: 10.1016/j.kint.2019.10.032

18. De Deyn PP, Vanholder R, D'Hooge R. Nitric oxide in uremia: effects of several potentially toxic guanidino compounds. *Kidney Int.* (2003) 63:S25-8. doi: 10.1046/j.1523-1755.63.s84.9.x

19. Kielstein JT, Donnerstag F, Gasper S, Menne J, Kielstein A, Martens-Lobenhoffer J, et al. Increases arterial stiffness and decreases cerebral blood flow in humans. *Stroke.* (2006) 37:2024–9. doi: 10.1161/01.STR.0000231640.32543.11

20. Zoccali C, Vanholder R, Massy ZA, Ortiz A, Sarafidis P, Dekker FW, et al. The systemic nature of CKD. *Nat Rev Nephrol.* (2017) 13:344–58. doi: 10.1038/nrneph.2017.52

21. Cheung WW, Paik KH, Mak RH. Inflammation and cachexia in chronic kidney disease. *Pediatr Nephrol.* (2010) 25:711–24. doi: 10.1007/s00467-009-1427-z